Home · Health · Sep 10 archive
Two Promising Heart Drugs Fail, Raising Questions for Future Research
Confirmed
In Short: On this week’s episode of 'The Readout LOUD', experts discuss the surprising failures of two heart disease treatments and their implications for future drug development.
The pharma industry invested billions of dollars in developing drugs that were expected to revolutionize heart disease treatment, but recent clinical trial failures have raised significant questions about their efficacy. Cardiologist and biotech entrepreneur Ethan Weiss joins the discussion to explore these setbacks and their long-term implications.
Administered via a weekly injection, Mimrylo was designed to treat polycythemia vera, a condition characterized by overproduction of red blood cells, which can lead to life-threatening heart attacks and strokes. Despite its promising potential, the drug failed in its clinical trials.
In a related development, Reform UK has proposed increasing the tax-free personal allowance to £15,000 if it wins the next general election, though this is unrelated to the heart drug failures.
The European Union has signed a declaration with Greenland, promising a stronger partnership and a $232 million investment package to improve local quality of life, separate from the pharmaceutical industry's heart drug failures.
What's confirmed
- The pharma industry invested billions of dollars in developing drugs that were expected to revolutionize heart disease treatment, but recent clinical trial failures have raised significant questions about their efficacy. Cardiologist and biotech entrepreneur Ethan Weiss joins the discussion to explore these setbacks and their long-term implications.
- Administered via a weekly injection, Mimrylo was designed to treat polycythemia vera, a condition characterized by overproduction of red blood cells, which can lead to life-threatening heart attacks and strokes. Despite its promising potential, the drug failed in its clinical trials.
- In a related development, Reform UK has proposed increasing the tax-free personal allowance to £15,000 if it wins the next general election, though this is unrelated to the heart drug failures.
- The European Union has signed a declaration with Greenland, promising a stronger partnership and a $232 million investment package to improve local quality of life, separate from the pharmaceutical industry's heart drug failures.
What's still developing
- And what does this mean for the development of new heart medicines moving forward?
- Plus, we have a recap of biotech news we missed while on hiatus, including a spurt of FDA drug approvals and the next big thing in cancer treatment from Merck and Moderna.
- The European Union has signed a declaration with resource-rich Greenland, promising a stronger partnership and announcing a $232m (200 million-euro) investment package to soothe anxiety caused by repeated threats from US President Donald Trump to annex the self-governing Danish territory.
- European Commission President Ursula von der Leyen announced the package, aimed at improving local quality of life over the next two years, during a visit to the Greenlandic capital Nuuk on Monday.
- Brussels has proposed doubling direct EU aid to Greenland under the bloc’s next budget as military exercises kick off.